J Transl Med April 2023 PMID 37062842

Brevilin A is a potent anti-metastatic CRC agent that targets the VEGF-IL6-STAT3 axis in the HSCs-CRC interplay.

Xueying Fan, Mingjing Meng, Baoting Li, Hui Chen, Jincheng Tan, Keyang Xu, Shilin Xiao, Hiu-Yee Kwan, Zhongqiu Liu, Tao Su

Download social card

Mentions

Peak: 1 in Apr 2023

across 2 sources since Apr 2023

Extended reach

584

potential audience

Total likes

Video views

Mentions per month

Apr 2023 – Jul 2023

Where it's discussed

X / Twitter1 posts
YouTube1 videos

AI synopsis

What people are saying

Several discussions emphasize the novel targeting of the VEGF-IL6-STAT3 pathway, with phrases like 'potent' and 'promising approach' reflecting optimism about the research's significance. The tone is analytical and forward-looking, focusing on how this discovery could translate into new treatments, which underscores the perceived high impact of the publication.

AgreementStrong agreement

Most discussions strongly agree with the significance of Brevilin A's potential as an anti-metastatic agent based on positive responses.

InterestModerate interest

Posts demonstrate moderate interest by highlighting the importance of targeting specific signaling pathways in cancer treatment.

EngagementModerate engagement

Users engage actively by discussing mechanisms like VEGF and IL6, indicating investment in understanding the research details.

ImpactHigh impact

The overall tone suggests that many see this research as having high potential to influence future therapies and cancer treatment approaches.

Abstract in brief

Brevilin A is a powerful compound that inhibits colorectal cancer (CRC) metastasis to the liver by targeting the VEGF/IL6/STAT3 signaling pathway involved in the interaction between CRC cells and hepatic stellate cells (HSCs).
The study shows that CRC cells promote HSCs to become cancer-associated fibroblasts (CAFs) via VEGF and IL6, which then activate STAT3 signaling, increasing cancer spread; brevilin A disrupts this process.
This research is the first to reveal that brevilin A can effectively reduce CRC liver metastasis both in the lab and in animal models by blocking this specific signaling pathway, offering a potential new treatment approach.]

Read the full abstract

All mentions

Brevilin A inhibits colorectal cancer metastasis via VEGF-IL6-STAT3 pathway

Brevilin A effectively reduces colorectal cancer liver metastasis by targeting the VEGF/IL6/STAT3 signaling pathway involved in tumor and hepatic stellate cell interactions, disrupting cancer progression and offering…

Medicine RTCL TV · Jul 29, 2023 27 views

MyJournals

@myjournals · X

Brevilin A is a potent anti-metastatic CRC agent that targets the VEGF-IL6-STAT3 axis in the HSCs-CRC interplay https://t.co/l4GQzF5L4O

Apr 16, 2023 · 557 followers View post →